-
Mashup Score: 5FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma - The ASCO Post - 2 month(s) ago
On March 7, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule BTK inhibitor zanubrutinib (Brukinsa) in combination with the anti-CD20 monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. The regimen was evaluated in S tudy BGB-3111-212 (ROSEWOOD; ClinicalTrials.gov identifier NCT03332017), an open-label, multicenter, randomized trial that enrolled 217 adult patients with
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia - PubMed - 2 month(s) ago
Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4U.S. Launches Antitrust Investigation of UnitedHealth - 2 month(s) ago
The Justice Department has launched an antitrust investigation into UnitedHealth Group, owner of the nation’s biggest health insurer.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Mechanisms of Formation of Antibodies against Blood Group Antigens That Do Not Exist in the Body - 3 month(s) ago
The system of the four different human blood groups is based on the oligosaccharide antigens A or B, which are located on the surface of blood cells and other cells including endothelial cells, attached to the membrane proteins or lipids. After transfusion, the presence of these antigens on the apical surface of endothelial cells could induce an immunological reaction against the host. The final oligosaccharide sequence of AgA consists of Gal-GlcNAc-Gal (GalNAc)-Fuc. AgB contains Gal-GlcNAc-Gal (Gal)-Fuc. These antigens are synthesised in the Golgi complex (GC) using unique Golgi glycosylation enzymes (GGEs). People with AgA also synthesise antibodies against AgB (group A [II]). People with AgB synthesise antibodies against AgA (group B [III]). People expressing AgA together with AgB (group AB [IV]) do not have these antibodies, while people who do not express these antigens (group O [0; I]) synthesise antibodies against both antigens. Consequently, the antibodies are synthesised again
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma | NEJM - 3 month(s) ago
Original Article from The New England Journal of Medicine — Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39Monoclonal gammopathies of clinical significance - 3 month(s) ago
Abstract. “Monoclonal gammopathy of clinical significance” (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. M
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40Monoclonal gammopathies of clinical significance - 3 month(s) ago
Abstract. “Monoclonal gammopathy of clinical significance” (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. M
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Monoclonal gammopathies of clinical significance - 3 month(s) ago
Abstract. “Monoclonal gammopathy of clinical significance” (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. M
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study - PubMed - 3 month(s) ago
Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd) in patients with RRMM …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@barttels2 @chadinabhan @AaronGoodman33 @Myeloma_Doc https://t.co/65ffdY4JGr All I can say as a community oncologist, Ello is well tolerated has some overall survival data in relapsed setting ( would never use it upfront ) Would consider it in some pts post Dara failure ( especially with ones who can’t get to Bispicefics: CarT)
-
-
Mashup Score: 1
The Dana-Farber Cancer Institute is reviewing more than 50 papers for research misconduct, including work of the hospital’s CEO.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet
Friday came early for FDA New approval of Zanu + Onintuzamab for relapsed Follicular @FDAOncology @OncBrothers https://t.co/LUmrWU09l0